Chicago Atlantic Real Estate Finance, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing. The company is an externally managed commercial mortgage REIT focused primarily on senior loans to state-licensed cannabis businesses.
Financial highlights
| Metric | 2023 | 2022 |
|---|---|---|
| Interest income | $62.9 million | $51.5 million |
| Interest expense | $5.8 million | $2.6 million |
| Net interest income | $57.1 million | $48.9 million |
| Total expenses | $18.6 million | $16.6 million |
| Net income | $38.7 million | $32.3 million |
| Basic / diluted EPS | $2.14 / $2.11 | $1.83 / $1.82 |
| Net cash from operations | $28.4 million | $17.0 million |
- Net income rose 20%; management attributed higher interest income to portfolio growth, higher Prime rates, and $3.5 million of prepayment fees and accelerated discounts/upfront fees, versus $1.2 million in 2022. Interest expense increased 120% as rates and borrowing costs rose.
- Distributable Earnings, a non-GAAP measure, were $41.5 million, or $2.30 per weighted-average basic share, versus $37.2 million, or $2.11, in 2022. Book value per share was $14.94 versus $14.86.
- At year-end, the company had $359.2 million in assets, $87.4 million in liabilities, and $271.9 million in stockholders’ equity. Revolver debt was $66.0 million; cash was $7.9 million. The $100 million facility had $34.0 million of unused capacity, and the company reported compliance with its financial covenants.
- Loans totaled $355.7 million in principal across 27 borrowers; net carrying value after a $5.0 million expected-credit-loss reserve was $348.7 million. The portfolio’s estimated weighted-average yield-to-maturity IRR was 19.4% (19.7% in 2022); weighted-average remaining life was 2.1 years.
- About 80.5% of loan principal was floating-rate. Management estimated that a 100-basis-point Prime-rate change would affect annual cash interest income by approximately $2.9 million and interest expense by approximately $0.7 million, before other effects.
- Operating, investing, and financing cash flows were $28.4 million, $(1.9) million, and $(24.3) million, respectively. Cash distributions declared for 2023 totaled $2.17 per share, including a $0.29 special dividend; $0.47 per share for the fourth quarter and the special dividend were paid in January 2024.
Material changes and unusual items
- Portfolio principal increased from $343.0 million to $355.7 million. New loan fundings were $92.2 million, while principal repayments were $76.9 million and loan-sale proceeds were $13.4 million.
- Two loans were placed on non-accrual in 2023. Loan #9, with $16.4 million principal, was past due more than 90 days at year-end; a related-party administrative agent acquired pledged subsidiary interests at auction and intended to sell assets for lenders. Loan #6, with $4.3 million principal, entered non-accrual in December, then was restored to accrual after a March 2024 amendment extending maturity to April 15 and capitalizing interest.
- Loan #8’s December amendment waived fourth-quarter cash interest and increased PIK interest; Loan #4’s amendments extended maturity and shifted interest to PIK. These changes make cash collection and repayment performance important to monitor.
- The expected-credit-loss provision fell to $0.9 million from $3.9 million, while the total year-end reserve rose to $5.0 million from $4.0 million. Management cited portfolio mix and a more stable rate environment, while noting the two non-accrual loans contributed to the reserve increase.
- Post-year-end, the revolver was amended to mature June 30, 2026, with an accordion allowing commitments up to $150 million. As of March 11, 2024, borrowings were $94 million and availability was $6 million. The filing also reports $16.5 million of loan advances from January 1 through March 11, 2024.
Outlook, risks and contingencies
- The company gave no specific earnings or dividend guidance. Management said it expects to grow the portfolio and may need additional equity or debt financing; it believes cash, available revolver capacity, and operating cash flows will cover requirements for at least the next 12 months. Future distributions remain at the board’s discretion and are not assured.
- Major risks include cannabis’s continued federal illegality, changing state rules, restricted banking access, and limits on transferring or foreclosing on cannabis-related licenses and properties. These constraints could delay or reduce recoveries on defaults.
- Credit, concentration, and liquidity risks are material: the top three borrowers represented 28.7% of funded principal; approximately 30% of the portfolio’s underlying real estate collateral value did not exceed the related loan balances. Appraisals may not represent realizable foreclosure-sale proceeds.
- PIK interest and original issue discounts can increase reported or taxable income before cash is received, potentially complicating liquidity and REIT distribution requirements. The company must also maintain REIT qualification and its Investment Company Act exemption.
- The manager is affiliated and receives base and incentive fees plus expense reimbursements. Total such compensation and reimbursements were $13.6 million in 2023, versus $9.7 million in 2022. The filing describes potential conflicts of interest.
- No material legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Loan #9’s collateral-sale progress, expected recovery, and treatment of the $1.5 million loan-specific reserve; also confirm its related-party status and non-accrual accounting.
- Loan #6’s post-year-end return to accrual, amended repayment terms, and whether cash interest is collected as scheduled; assess Loan #4 and Loan #8 amendments and other borrower payment trends.
- Whether the $5.0 million CECL reserve adequately reflects borrower credit deterioration, collateral values, and cannabis-market recovery constraints.
- Current revolver borrowings, remaining availability, borrowing costs, collateral requirements, and compliance with covenants after the 2024 amendment.
- Cash-based dividend coverage, given 2023 declared distributions of $2.17 per share versus $2.30 of non-GAAP Distributable Earnings per basic share and the portfolio’s PIK income.
- The assumptions underlying the 19.4% estimated loan yield and appraised collateral coverage, including the likelihood of fees, prepayments, and recovery at maturity.